Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, MA 02210
Phone: (617) 341-6100Website: https://www.vrtx.com/Careers: vrtx.wd5.myworkdayjobs.com/vertex_careersPatient Assistance Program: www.vrtx.com/medicines/patient-support
Latest news
- FDA Approves Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
30 January 2025 - FDA Approves Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) for the Treatment of Cystic Fibrosis
20 December 2024 - Vertex Announces U.S. FDA Approval for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del Trikafta-Responsive Variants
20 December 2024 - Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
19 December 2024 - Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
30 July 2024 - Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
2 July 2024 - Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
18 April 2024 - Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
5 February 2024 - Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
30 January 2024 - Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine
3 August 2023
Drugs Associated with Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated manufactures, markets and/or distributes more than 7 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Alyftrek
Generic name: deutivacaftor/tezacaftor/vanzacaftor Drug class: CFTR combinations |
||
|
Casgevy
Generic name: exagamglogene autotemcel Drug class: miscellaneous uncategorized agents |
||
|
Journavx
Generic name: suzetrigine Drug class: miscellaneous analgesics |
||
|
Kalydeco
Generic name: ivacaftor Drug class: CFTR potentiators |
1 review | 10 / 10 |
|
Orkambi
Generic name: ivacaftor/lumacaftor Drug class: CFTR combinations |
||
|
Symdeko
Generic name: ivacaftor/tezacaftor Drug class: CFTR combinations |
||
|
Trikafta
Generic name: elexacaftor/ivacaftor/tezacaftor Drug class: CFTR combinations |
1 review | 9.0 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||